Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

203.55 -0.32 (-0.16%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
AbbVie Stock Price Forecast: $200 On The Cards?
Strategic partnerships and acquisitions enhance AbbVie's pipeline. 
Via Talk Markets
Here's How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years
Via Benzinga
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for June 2024
Discover top retirement stocks with strong buy ratings, offering reliable growth and income to ensure a comfortable retirement. 
Via InvestorPlace
Topics Retirement
Exposures Pension
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding can build huge amounts of passive income. 
Via The Motley Fool
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
Discover these blue-chip stocks to buy in the biotechnology, banking, pharmaceuticals, tobacco, restaurants, and entertainment industries. 
Via InvestorPlace
Earn Income While Playing The Hottest Sectors
Via Talk Markets
Looking Into AbbVie's Recent Short Interest
Via Benzinga
Comparative Study: AbbVie And Industry Competitors In Biotechnology Industry
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,100 Today
Via Benzinga
3 High-Dividend Stocks to Buy and Hold Forever: June 2024 Edition
Looking for high-yield dividend stocks to buy and hold? Take a look at these three buy-rated Dividend Aristocrats. 
Via InvestorPlace
2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
Don't sleep on the value of quality dividends. 
Via The Motley Fool
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Nvidia, AbbVie, Vertex Pharmaceuticals And An Oil Giant: CNBC's 'Final Trades'
On CNBC's Halftime Report, Bryn Talkington picked NVIDIA, Jim Lebenthal chose Vertex Pharmaceuticals, Kevin Simpson named ConocoPhillips, and Rob Sechan suggested AbbVie, with all four stocks having... 
Via Benzinga
2 Dividend Stocks That Could Pay You for Life
There are other reasons to love these businesses, too. 
Via The Motley Fool
Analyst Scoreboard: 6 Ratings For AbbVie
Via Benzinga
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
The Dividend Defenders: 3 Stocks That Will Protect and Grow Your Wealth Dividend Stocks
Are you looking for some defenders for your portfolio? Here are three dividend stocks to protect and grow your wealth. 
Via InvestorPlace
Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
Thanks to the predictability of big businesses, the bargains found among undervalued blue-chip stocks are simply more trustworthy. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance... 
Via Benzinga
AbbVie, Amazon, Goldman Sachs And 2 Major Health Care Stocks On CNBC's 'Final Trades'
AbbVie Inc. has good dividend yield and attractive valuations, according to Jim Lebenthal of Cerity Partners. 
Via Benzinga
AbbVie's Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients
AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate. 
Via Benzinga
Investing in Biotech: High Risk for a Potentially High Reward
Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit. 
Via MarketBeat
7 Stocks That Could Safely 10X by 2030
Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align. 
Via InvestorPlace
Hedge Fund Favorites: 7 Stocks to Buy When You’re Feeling Jittery
With the hedge funds targeting certain ideas with their vast resources, retail investors can ride coattails with these stocks to buy. 
Via InvestorPlace
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
If you have the patience and the ability to take a little risk, consider these three biotech stocks to buy since they can really pay off. 
Via InvestorPlace
2 High-Yield Dividend Stocks to Buy Right Now
These two high-yield dividend stocks are top buys right now. 
Via The Motley Fool
The Dividend Dominators: 3 Stocks That Will Make Your Portfolio Reign Supreme
Top dividend stocks across various sectors continue to reward investors, even as they face sales shortfalls and leadership changes. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
69 70 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.